RS Research is a clinical stage biotechnology start-up developing novel nanomedicines based on innovative drug delivery platforms for therapies to treat patients fighting cancer.
RS Research aims to develop drugs that can reduce side effects and increase the effect of chemotherapy.
RS Research was founded in 2015 by Sena Nomak and Rana Sanyal. The company is headquartered in Istanbul, Turkey, with branch in Switzerland named PDC Therapeutics.
RS Research has discovered a novel drug delivery platform with which five different development programs are currently ongoing in various preclinical and clinical stages for therapies to treat patients with lung, breast, prostate, pancreas and ovarian cancers.
RS Research's nanocarrier platform (Sagitta®) is highly tunable with a plug & play approach, allowing rapid development of targeted nanomedicines with superior performance aiming multiple indications.
RS Research's GMP certified production facility is the first cytotoxic-capable clinical batch-size contract organization for such services in the region.
RS Research is backed by GEN Ilaç, OneLife Ventures, Eczacıbaşı Momentum, and others. The company raised $12M in a Series A round on Dec 17, 2021. This brings RS Research's total funding to $14.3M to date.